首页> 美国卫生研究院文献>other >Characterization of Optically Resolved 9-fluoropropyl-dihydrotetrabenazine as a Potential PET Imaging Agent Targeting Vesicular Monoamine Transporters
【2h】

Characterization of Optically Resolved 9-fluoropropyl-dihydrotetrabenazine as a Potential PET Imaging Agent Targeting Vesicular Monoamine Transporters

机译:表征光学拆分的9-氟丙基-二氢丁苯那嗪作为潜在的PET成像剂靶向水泡单胺转运蛋白。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Labeling derivatives of dihydrotetrabenazine (DTBZ) with F-18 (T1/2 = 110 min) instead of C-11 (T1/2 = 20 min), would improve their utility and availability for imaging vesicular monoamine transporters (VMAT2) in clinical settings. The successful synthesis, reported previously, of two novel 9-fluoroalkyl(±)-DTBZ ligands prompted us to study the optically resolved active ligand 9-fluoropropyl-(+)-DTBZ (FP-(+)-DTBZ), which may have more promising characteristics. The inhibition constant (Ki) estimated for FP-(+)-DTBZ (using [3H](±)-DTBZ as the labeled ligand in rat striatal homogenates) showed a lower value as compared to the racemic FP-(±)-DTBZ (0.10 ± 0.01 vs 0.19 ± 0.04 nM). The inactive isomer, FP-(−)-DTBZ, displayed a much lower binding affinity with a Ki value >3000 nM. Biodistribution studies in mice after an iv injection of [18F]FP-(+)-DTBZ exhibited a ratio of striatum (ST, target) to cerebellum (CB, background) of 4.51 at 30 minutes post-injection, which is a higher value than previously obtained with the racemic ligand [18F]FP-(±)-DTBZ (ST/CB = 2.95). Brain extraction at 30 minutes after the tracer injection in mice showed that >95% of the radioactivity corresponded to the parent, non-metabolized, compound remaining in the striatum, suggesting that the tracer has an excellent in vivo stability. Furthermore, localization of the tracer in the brain examined with ex vivo autoradiography displayed a typical distribution pattern consistent with VMAT2 sites. The highest labeling was observed in monoaminergic neuron regions (caudate putamen, olfactory tubercle, nucleus accumbens, substania nigra, dorsal raphe and locus coerules). We also tested the selective labeling of this tracer at the dopamine neurons in unilateral-lesioned mice (treated with 6-hydroxydopamine). When [18F]FP-(+)-DTBZ and [125I]IPT ((N-(3'-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane, a selective marker for dopamine transporters in dopaminergic neurons) were simultaneously injected into lesioned mice, we observed an excellent correlation (r = 0.95) for these tracers. From these findings, we conclude that [18F]FP-(+)-DTBZ is a sensitive and selective tracer for VMAT2 binding sites and it may be useful for in vivo evaluation of diseases relating to changes of monoamine neuronal integrity.
机译:用F-18(T1 / 2 = 110分钟)而不是C-11(T1 / 2 = 20分钟)标记二氢丁苯那嗪(DTBZ)的衍生物,将改善其在临床环境中对水泡单胺转运蛋白(VMAT2)成像的实用性和可用性。先前报道的两个新型9-氟烷基(±)-DTBZ配体的成功合成促使我们研究了光学拆分的活性配体9-氟丙基-(+)-DTBZ(FP-(+)-DTBZ),更有前途的特征。与FP-(+)-DTBZ(使用[ 3 H](±)-DTBZ作为大鼠纹状体匀浆中的标记配体)估计的抑制常数(Ki)相比,外消旋FP-(±)-DTBZ(0.10±0.01 vs 0.19±0.04 nM)。非活性异构体FP-(-)-DTBZ显示出低得多的结合亲和力,Ki值> 3000 nM。静脉注射[ 18 F] FP-(+)-DTBZ后在小鼠中的生物分布研究显示,在30分钟后,纹状体(ST,靶标)与小脑(CB,背景)的比率为4.51 -注射,其比先前使用外消旋配体[ 18 F] FP-(±)-DTBZ(ST / CB = 2.95)获得的值高。小鼠注射示踪剂后30分钟的脑部提取显示,> 95%的放射性对应于残留在纹状体中的母体未代谢化合物,表明示踪剂具有出色的体内稳定性。此外,用离体放射自显影检查的示踪剂在脑中的定位显示出与VMAT2位点一致的典型分布模式。在单胺能神经元区域(尾状壳核,嗅结节,伏隔核,黑质,黑背叶和轨迹小核)中观察到最高的标记。我们还测试了单侧病变小鼠(用6-羟基多巴胺处理)多巴胺神经元中该示踪剂的选择性标记。当[ 18 F] FP-(+)-DTBZ和[ 125 I] IPT((N-(3'-iodopropen-2'-yl)-2-同时将β-碳甲氧基-3-β-(4-氯苯基)托烷(多巴胺能神经元中多巴胺转运蛋白的选择标记)注入病变小鼠中,我们发现这些示踪剂具有极好的相关性(r = 0.95)。我们得出的结论是[ 18 F] FP-(+)-DTBZ是VMAT2结合位点的敏感和选择性示踪剂,它可能对与单胺神经元完整性变化有关的疾病进行体内评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号